Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Novartis AG (NVS) and Encourages Investors to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / September 22, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novartis AG ("Novartis" or "the Company") (NYSE:NVS). Investors who purchased Novartis securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/cases/novartis-ag-nvs-class_action_lawsuit.

Novartis Investigation Details

On September 8, 2026, Novartis issued a press release "announcing that the global Phase III HARBOR study evaluating del-desiran in people living with myotonic dystrophy type 1 (DM1) did not demonstrate statistically significant improvement versus placebo on the primary endpoint of video hand opening time (vHOT), a novel measure of hand myotonia." On this news, Novartis's American Depositary Share ("ADS") price fell $22.29 per ADS, or 13.93%, to close at $137.70 per ADS on September 8, 2026.

What's Next for Novartis Investors?

If you are aware of any facts relating to this investigation or purchased Novartis securities, you can assist this investigation by visiting the firm's site: bgandg.com/cases/novartis-ag-nvs-class_action_lawsuit. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911

No Cost to Novartis Investors

We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Novartis Securities Investigation?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | info@bgandg.com

Attorney advertising.

Prior results do not guarantee similar outcomes.

SOURCE: Bronstein, Gewirtz & Grossman, LLC

View the original press release on ACCESS Newswire